In oesophageal ca which Neoadjuvant chemotherapy is used :

Ans. is 'a' ie Cisplatin Sabiston writes-" Since its introduction in 1980, cisplatin has emerged as the cornerstone of combination therapy in esophageal cancer. As a single agent, it has a response rate of 25% to 30%. Given in combination with 5- fluorouracil, a response rate of 50% may be achieved, and this is an established chemotherapeutic regimen for esophageal cancer. "